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Journal of Stroke and CBackground: Stroke trials often analyzepatientswithheterogeneousprognosesusing a
single definition of outcome, whichmay not be applicable to all subgroups.We aimed
to evaluate the treatment effects of MCL601 among patients stratified by prognosis in
the Chinese Medicine Neuroaid Efficacy on Stroke Recovery (CHIMES) study.
Methods: Analyses were performed using data from the CHIMES study, an interna-
tional, randomized, placebo-controlled, double-blind trial comparing MLC601 with
placebo in patients with ischemic stroke of intermediate severity in the preceding
72 hours. All subjects with baseline data and the modified Rankin Scale (mRS) score
at 3 months were included. Results: Data from 1006 subjects were analyzed. The pre-
dictive variables for mRS score greater than 1 at month 3 were age older than 60 years
(P , .001), baseline National Institutes of Health Stroke Scale score 10-14 (P , .001),
stroke onset to initiation of study treatment of more than 48 hours (P , .001), and fe-
male sex (P 5 .026). A higher number of predictors was associated with poorer mRS
score atmonth 3 for both placebo (P, .001) and treatment (P, .001) groups. The odds
ratio (OR) for achieving a good outcome increased with the number of predictors and
reached statistical significance in favor of MLC601 among patients with 2 to 4 predic-
tors combined (unadjusted OR 5 1.44, 95% confidence interval, 1.02-2.03; adjusted
OR 5 1.60, 95% confidence interval, 1.10-2.34). Conclusions: Age, sex, baseline Na-
tional Institutes of Health Stroke Scale score, and time to first dose are predictors of
functional outcome in the CHIMES study. Stratification by prognosis showed that pa-
tients with 2 or more predictors of poorer outcome have better treatment effect with
MLC601 than patients with single or no prognostic factor. These results have implica-
tions on designing future stroke trials. Key Words: Acute stroke—stroke recovery—
MLC601—NeuroAiD—prognosis—clinical trial.
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S. CHANKRACHANG ET AL.824Introduction
Some of the difficulties in translating acute stroke treat-
ments from bench to bedside have been attributed to dis-
crepancies between preclinical and clinical study
designs.1-3 Unlike preclinical studies, stroke clinical
trials often include heterogeneous patients4 who are usu-
ally analyzed together using a single definition of ‘‘good’’
outcome that may not be applicable to all patient sub-
groups.
Using a prognosis-based approach to target patient se-
lection or define and adjust desired outcomes have been
proposed by several groups.5-9 Trials that implemented
such approach have identified cohorts with specific
prognostic profiles likely to benefit or be harmed by
treatments.10-12
MLC601 has been shown to have both neurorestorative
and neuroprotective properties in animal and cellular
models.13 Clinical trials suggest that MLC601, as an
add-on to standard treatment, could be effective in
improving functional outcome and motor recovery and
is safe for patients with primarily nonacute stable
stroke.14
In a recent publication, the favorable treatment effect of
MLC601 in patients with acute ischemic stroke recruited
from the Philippines in the Chinese Medicine Neuroaid
Efficacy on Stroke recovery (CHIMES) study was hypoth-
esized to be because of inclusion of patients with poorer
prognosis.15 In this analysis, we aimed to evaluate if treat-
ment effect of MCL601 varies among acute stroke patients
with differing prognostic profiles in the CHIMES study
cohort and if stratification by anticipated prognosis may
identify patients more likely to benefit from MLC601.Methods
Analyses were performed using data from the CHIMES
study, an international, randomized, placebo-controlled,
double-blind trial that compared MLC601 with placebo
in patients with ischemic stroke of intermediate severity
in the preceding 72 hours (clinicaltrials.gov
NCT00554723).16-18 Subjects were allocated to either
MLC601 or placebo for 3 months as add-on to standard
stroke care (ie, antiplatelet therapy, control of vascular
risk factors, appropriate rehabilitation) and followed for
3 months. The primary outcome measure used in this
study was the modified Rankin scale (mRS) score at
3 months. Of 1099 subjects in the CHIMES study, 1006
with complete baseline data and an mRS score at month
3 were included in this post hoc analysis. Logistic regres-
sion analyses were performed to identify predictors of
mRS score greater than 1 and to assess the association be-
tween number of predictors and mRS. Sensitivity, speci-
ficity, positive predictive values, negative predictive
values, and receiver operating characteristic for mRS
score less than 2 versus 2 or more at month 3 were calcu-lated. Odds ratios (ORs) and the corresponding 95% con-
fidence intervals (CIs) were used to estimate treatment
effects overall and according to number of predictors.
ORs were also adjusted by logistic regression for baseline
prognostic factors, that is, age, sex, National Institutes of
Health Stroke Scale (NIHSS), prestroke mRS, and dura-
tion from stroke onset to initiation of study treatment.Results
Baseline characteristics of patients were similar be-
tween the treatment groups as previously described.16,18
The predictive variables for mRS score greater than 1 at
month 3 were age older than 60 years (P , .001),
baseline NIHSS score of 10-14 (P , .001), stroke onset to
initiation of study treatment of more than 48 hours
(P , .001), and female sex (P 5 .026). Increasing number
of predictors at baseline was associated with worse mRS
score at month 3 for both placebo (P , .001) and
treatment (P , .001) groups (Fig 1). A high response
rate in the placebo group (.50% with mRS score , 2)
was seen among subjects with one or no predictor of
poorer mRS. Having more than 1 predictor has a sensi-
tivity of 72%, specificity of 61%, positive predictive value
of 68%, and negative predictive value of 64% for a poorer
outcome of mRS score greater than 1 at 3 months (Table 1).
Receiver operating characteristic area under the curve
was .7211.
The overall OR of MLC601 for achieving an mRS score
less than 2 at month 3 was 1.15 (95% CI, .89-1.47). Stratifi-
cation according to number of predictors of poorer
outcome showed ORs increasing with the number of pre-
dictors and reached statistical significance in favor of
MLC601 among subjects with 2 or more predictors
(OR 5 1.44, 95% CI, 1.02-2.03) and was higher in those
with 3 or more predictors (OR 5 2.21, 95% CI, 1.22-4.0;
Fig 2). Adjustment for baseline prognostic factors gener-
ally increased the ORs.Discussion
Age, stroke severity, sex, and time delay to treatment
have been identified as predictors of outcome after a
stroke in this and many previous studies.19 Aside from
sex, these factors are often eligibility criteria in stroke clin-
ical trials. In addition to being individually predictive of
outcome in the CHIMES cohort, we found a strong
graded association between the number of predictors
and mRS status at 3 months.
The CHIMES study showed an overall OR of achieving
mRS score less than 2 in favor of MLC601, although this
did not reach statistical significance.16 This may be
because of inclusion of patients with relatively good prog-
nosis. In the CHIMES study, patients were included if
they were 18 years and older, had a baseline NIHSS score
of 6 to 14, and stroke onset in the preceding 72 hours. The
Figure 1. Relationship between number of predictors and the mRS score at month 3 among MLC601- and placebo-treated patients in the CHIMES study. Ab-
breviations: CHIMES, Chinese Medicine Neuroaid Efficacy on Stroke Recovery; CI, confidence interval; mRS, modified Rankin Scale; OR, odds ratio.
PROGNOSIS AND TREATMENT EFFECT IN CHIMES 825stroke severity and treatment window eligibility criteria
were chosen to target inclusion of patients who would
have the potential to improve over time. Although suc-
cessfully excluding very severe patients with poor prog-
nosis for recovery from our cohort, that is, only less
than 5% dead or completely disabled, the NIHSS cutoff
appeared to have led to selection of many patients with
excellent prognosis with almost half in the placebo group
achieving functional independence (mRS score , 2) and
more than two thirds achieving an mRS score of 0 to 2
at month 3. Such high response rate in the placebo arm
and inclusion of subjects with prognostic heterogeneity
have been shown to affect the potential of detecting treat-
ment effects in clinical trials.11,20,21Indeed, our present analysis on the entire CHIMES
cohort shows that MLC601 may be beneficial in patients
with predicted poorer outcome based on baseline prog-
nostic variables. This supports the hypothesis from a
recently published subgroup analysis of the Filipino
cohort that the favorable treatment effects of MLC601
may have been because of inclusion of more patients
with poorer prognosis.15 Clinicians are familiar with the
concept that the potential of a patient to recover fromadis-
order or derive benefit from a treatment depends on dis-
ease severity and prognosis. Such potential benefit
expectedly would not be as obvious in patients who either
would spontaneously recover fully regardless of interven-
tion or are too severe to realistically improve completely.22
Table 1. Sensitivity, specificity, PPV, and NPV according to











.0 94.2 28.7 61.1 80.5
.1 71.5 60.9 68.5 64.2
.2 35.4 90.4 81.5 54.0
.3 6.9 98.7 86.4 47.1
Abbreviations: NPV, negative predictive value; PPV, positive
predictive value.
S. CHANKRACHANG ET AL.826Our results have implications for the design of future
stroke trials as also raised by other groups.2-12 In clinical
trials, caution must be observed when deciding on the
outcomes and a threshold for assessing such outcomes to
be defined as ‘‘good response.’’5 In addition, adjusting out-
comes according to baseline prognosiswould improve the
statistical power of detecting an effect,8 which in our study
generally increased the estimates of the treatment effects.
The anticipated prognosis and potential to respond to
treatment should be considered in selecting a study pop-
ulation. Although not always successful,23-25 targeting
patients with greater potential to benefit from therapy
may reduce the sample size required in trials without
affecting the power.7 Based on the mRS distribution in
our sample, approximately 7000 subjects would be
needed to have 90% power to detect an overall OR of
1.15. The sample size required, however, could be greatly
reduced to 1200 for detecting an OR of 1.44 by recruiting
only subjects with more than 1 predictor and further
reduced to 300 for an OR of 2.21 with inclusion of only
subjects with more than 2 predictors. As patients with
poor prognostic predictors are not uncommon in stroke,
prognosis-based patient selection may be feasible. Eligi-
bility criteria that are too restrictive, however, may lead
to more screen failures, slow recruitment, and lessgeneralizable results. Careful balancing of eligibility
criteria or their combinations is needed to achieve prog-
nostic homogeneity.
On the other hand, the concern with the strategy of
reducing sample size is that it gives little room to accom-
modate any variation in the outcomes that may not have
been expected from earlier phase studies, which it was
based on. Larger sample sizes can help mitigate this risk.
In large stroke trials where patient homogeneity may not
be practical and may need to be balanced with the disad-
vantages of having more stringent eligibility, some have
proposed a prognosis-based responder analysis, which
may be implemented by defining a realistic, clinically
important difference relative to the expected outcome of
study subjects. In this analysis, also called sliding dichot-
omy, subjects are grouped into a number of bands accord-
ing to baseline prognosis, wherein each band is analyzed
according to a customized predefined ‘‘good’’ and ‘‘bad’’
outcome on a scale.6 This was performed in the Interna-
tional Surgical Trial in Intracerebral Hemorrhage studies
but failed to show statistical significance.25,26
There are some limitations in this study. The prognostic
variables we identified will need to be externally vali-
dated in another data set, although each was already
often shown to be important predictive variables in
many other studies.19 The analyses were post hoc, and
the trial was not originally planned for such prognosis-
based analysis. However, the data used were collected
before unblinding.
In summary, prognostic factors for functional outcomes
are age, sex, stroke severity, and stroke onset to treatment
delay. Using such factors in a prognosis-based stratified
analysis showed that MLC601 had a treatment effect
among patients with at least 2 predictors of poor outcome.
Future trial designs should consider selection of patients
with moderate baseline stroke severity and in whom
treatment could not be instituted earlier than 48 hours
from onset.Figure 2. Treatment effects according to num-
ber of predictors in the CHIMES study. Abbrevi-
ations: CHIMES, Chinese Medicine Neuroaid
Efficacy on Stroke Recovery; CI, confidence in-
terval; NIHSS, National Institutes of Health
Stroke Scale; OR, odds ratio.
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